A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
Public ClinicalTrials.gov record NCT02302079. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate efficacy and safety of ASP8232 in subjects with diabetic macular edema (DME). This study will evaluate the percent change from baseline in excess central subfield thickness (CST) in the study eye as assessed by spectral domain-optical coherence Tomography (SD-OCT) for ASP8232 monotherapy at Month 3.
Study identification
- NCT ID
- NCT02302079
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 96 participants
Conditions and interventions
Conditions
Interventions
- ASP8232 Drug
- ranibizumab Drug
- Placebo Drug
- Sham intravitreal (IVT) injection Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 12, 2015 (Actual)
- Primary completion
- Aug 12, 2016 (Actual)
- Completion
- Aug 12, 2016 (Actual)
- Last update posted
- Oct 31, 2024
2015 – 2016
United States locations
- U.S. sites
- 21
- U.S. states
- 11
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site US10021 | Phoenix | Arizona | 85104 | — |
| Site US10025 | Tucson | Arizona | 85704 | — |
| Site US10006 | Arcadia | California | 91007 | — |
| Site US10004 | Beverly Hills | California | 90211 | — |
| Site US10007 | Palm Desert | California | 92260 | — |
| Site US10011 | Sacramento | California | 95819 | — |
| Site US10031 | Santa Ana | California | 92705 | — |
| Site US10029 | Golden | Colorado | 80401 | — |
| Site US10016 | Miami | Florida | 33126 | — |
| Site US10005 | Winter Haven | Florida | 33880 | — |
| Site US10036 | Augusta | Georgia | 30909 | — |
| Site US10002 | Boston | Massachusetts | 02114 | — |
| Site US10001 | Omaha | Nebraska | 985540 | — |
| Site US10027 | Reno | Nevada | 89511 | — |
| Site US10012 | Nashville | Tennessee | 37203 | — |
| Site US10010 | Abilene | Texas | 79606 | — |
| Site US10015 | Austin | Texas | 78705 | — |
| Site US10013 | Houston | Texas | 77030 | — |
| Site US10030 | McAllen | Texas | 78503 | — |
| Site US10009 | San Antonio | Texas | 78240-1502 | — |
| Site US10017 | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02302079, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 31, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02302079 live on ClinicalTrials.gov.